These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31296227)

  • 21. Genetic susceptibility to Dupuytren's disease: transforming growth factor beta receptor (TGFbetaR) gene polymorphisms and Dupuytren's disease.
    Bayat A; Stanley JK; Watson JS; Ferguson MW; Ollier WE
    Br J Plast Surg; 2003 Jun; 56(4):328-33. PubMed ID: 12873459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of matrix metalloproteinases and their inhibitors in cords and nodules of patients with Dupuytren's disease.
    Ulrich D; Ulrich F; Piatkowski A; Pallua N
    Arch Orthop Trauma Surg; 2009 Nov; 129(11):1453-9. PubMed ID: 18758795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An integrated proteomics approach for studying the molecular pathogenesis of Dupuytren's disease.
    Kraljevic Pavelic S; Sedic M; Hock K; Vucinic S; Jurisic D; Gehrig P; Scott M; Schlapbach R; Cacev T; Kapitanovic S; Pavelic K
    J Pathol; 2009 Mar; 217(4):524-33. PubMed ID: 19089850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IGF-II and IGFBP-6 regulate cellular contractility and proliferation in Dupuytren's disease.
    Raykha C; Crawford J; Gan BS; Fu P; Bach LA; O'Gorman DB
    Biochim Biophys Acta; 2013 Oct; 1832(10):1511-9. PubMed ID: 23623986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of stem cells in Dupuytren's disease.
    Hindocha S; Iqbal SA; Farhatullah S; Paus R; Bayat A
    Br J Surg; 2011 Feb; 98(2):308-15. PubMed ID: 21104823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vitamin D status in Dupuytren's disease: Association with clinical status and vitamin D receptor expression.
    Park JW; Kim ST; Lee KS; Gong HS
    J Plast Reconstr Aesthet Surg; 2022 Jun; 75(6):1916-1922. PubMed ID: 35131190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A complete expression profile of matrix-degrading metalloproteinases in Dupuytren's disease.
    Johnston P; Chojnowski AJ; Davidson RK; Riley GP; Donell ST; Clark IM
    J Hand Surg Am; 2007 Mar; 32(3):343-51. PubMed ID: 17336841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The importance of genetic susceptibility in Dupuytren's disease.
    Becker K; Tinschert S; Lienert A; Bleuler PE; Staub F; Meinel A; Rößler J; Wach W; Hoffmann R; Kühnel F; Damert HG; Nick HE; Spicher R; Lenze W; Langer M; Nürnberg P; Hennies HC
    Clin Genet; 2015 May; 87(5):483-7. PubMed ID: 24749973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. WNT2 locus is involved in genetic susceptibility of Peyronie's disease.
    Dolmans GH; Werker PM; de Jong IJ; Nijman RJ; ; Wijmenga C; Ophoff RA
    J Sex Med; 2012 May; 9(5):1430-4. PubMed ID: 22489561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metalloproteinase gene expression correlates with clinical outcome in Dupuytren's disease.
    Johnston P; Larson D; Clark IM; Chojnowski AJ
    J Hand Surg Am; 2008 Sep; 33(7):1160-7. PubMed ID: 18762113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Genetic aspect of Dupuytren's diseases].
    Bobiński R; Olczyk K; Wisowski G; Janusz W
    Wiad Lek; 2004; 57(1-2):59-62. PubMed ID: 15181751
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of bone morphogenetic proteins by Dupuytren's fibroblasts.
    Shin SS; Liu C; Chang EY; Carlson CS; Di Cesare PE
    J Hand Surg Am; 2004 Sep; 29(5):809-14. PubMed ID: 15465229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Dupuytren's disease. State of the art and therapeutic perspectives].
    Corrado A; Cantatore FP
    Reumatismo; 2007; 59(2):118-28. PubMed ID: 17603691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. What do we know about managing Dupuytren's disease cost-effectively?
    Dritsaki M; Rivero-Arias O; Gray A; Ball C; Nanchahal J
    BMC Musculoskelet Disord; 2018 Jan; 19(1):34. PubMed ID: 29370792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Involvement of pro-inflammatory cytokines and growth factors in the pathogenesis of Dupuytren's contracture: a novel target for a possible future therapeutic strategy?
    Bianchi E; Taurone S; Bardella L; Signore A; Pompili E; Sessa V; Chiappetta C; Fumagalli L; Di Gioia C; Pastore FS; Scarpa S; Artico M
    Clin Sci (Lond); 2015 Oct; 129(8):711-20. PubMed ID: 26201022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Free radicals and Dupuytren's contracture.
    Murrell GA; Francis MJ; Bromley L
    Br Med J (Clin Res Ed); 1987 Nov; 295(6610):1373-5. PubMed ID: 2825907
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is Dupuytren's disease caused by an imbalance between proliferation and cell death?
    Jemec B; Grobbelaar AO; Wilson GD; Smith PJ; Sanders R; McGrouther DA
    J Hand Surg Br; 1999 Oct; 24(5):511-4. PubMed ID: 10597921
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dupuytren's disease metabolite analyses reveals alterations following initial short-term fibroblast culturing.
    Rehman S; Xu Y; Dunn WB; Day PJ; Westerhoff HV; Goodacre R; Bayat A
    Mol Biosyst; 2012 Sep; 8(9):2274-88. PubMed ID: 22772395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene expression analysis of Dupuytren's disease: the role of TGF-beta2.
    Zhang AY; Fong KD; Pham H; Nacamuli RP; Longaker MT; Chang J
    J Hand Surg Eur Vol; 2008 Dec; 33(6):783-90. PubMed ID: 18694919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgen receptors in Dupuytren's contracture.
    Pagnotta A; Specchia N; Greco F
    J Orthop Res; 2002 Jan; 20(1):163-8. PubMed ID: 11853085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.